Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria and Chronic Kidney Disease
NextSource Materials Signs Agreement for the Supply of Graphite Fines as Additional Source of Feedstock for its Battery Anode Facility in Abu Dhabi
